argenx NV ADR (ARGX)vsNovavax Inc (NVAX)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
NVAX
Novavax Inc
$9.34
+0.86%
HEALTHCARE · Cap: $1.57B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 277% more annual revenue ($4.24B vs $1.12B). NVAX leads profitability with a 39.2% profit margin vs 30.5%. ARGX appears more attractively valued with a PEG of 0.83. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
NVAX
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+48.9%
Fair Value
$17.54
Current Price
$9.34
$8.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Revenue surging 66.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Smaller company, higher risk/reward
ROE of -9.0% — below average capital efficiency
Earnings declined 38.1%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : NVAX
The strongest argument for NVAX centers on P/E Ratio, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.2% and operating margin at 14.2%. Revenue growth of 66.6% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : NVAX
The primary concerns for NVAX are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
NVAX carries more volatility with a beta of 2.63 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (63/100 vs 56/100), backed by strong 30.5% margins and 73.0% revenue growth. NVAX offers better value entry with a 48.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Novavax Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?